{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:35Z","timestamp":1790395475035,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.nefroe.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:27:07Z","timestamp":1683793627000},"page":"217-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9174-0351","authenticated-orcid":false,"given":"Hakan","family":"Ozer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-5490","authenticated-orcid":false,"given":"Ismail","family":"Baloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0608-1641","authenticated-orcid":false,"given":"Ali","family":"Topkac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-2677","authenticated-orcid":false,"given":"Yasin","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-3170","authenticated-orcid":false,"given":"Fethi","family":"Yonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-8937","authenticated-orcid":false,"given":"Furkan","family":"Dagl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-7557","authenticated-orcid":false,"given":"\u0130brahim","family":"Kilinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-7716","authenticated-orcid":false,"given":"Kultigin","family":"Turkmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2023.05.002_bib0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0130","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0135","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0140","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0145","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/1873-3468.13091","article-title":"Structural characterizations of human periostin dimerization and cysteinylation","volume":"592","author":"Liu","year":"2018","journal-title":"FEBS Lett"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0150","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.juro.2011.05.042","article-title":"Expression patterns and roles of periostin during kidney and ureter development","volume":"186","author":"Sorocos","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0155","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.90266.2008","article-title":"Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor","volume":"295","author":"Wallace","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0160","doi-asserted-by":"crossref","first-page":"22649","DOI":"10.18632\/aging.203580","article-title":"Effects of periostin deficiency on kidney aging and lipid metabolism","volume":"13","author":"An","year":"2021","journal-title":"Aging (Albany, NY)"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0165","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s11255-020-02546-3","article-title":"Fabry disease: where are we now?","volume":"52","author":"Turkmen","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0170","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1007\/s00018-017-2648-0","article-title":"Periostin in inflammation and allergy","volume":"74","author":"Izuhara","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0175","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5114\/ceji.2021.110317","article-title":"The role of periostin in kidney diseases","volume":"46","author":"Turczyn","year":"2021","journal-title":"Cent J Immunol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0180","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0961203314566634","article-title":"Periostin: a novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis patients","volume":"24","author":"Wantanasiri","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0185","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ajpath.2011.06.002","article-title":"Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis","volume":"179","author":"Sen","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0190","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2013060664","article-title":"Inhibition of periostin expression protects against the development of renal inflammation and fibrosis","volume":"25","author":"Mael-Ainin","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0195","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biochi.2019.03.003","article-title":"Periostin contributes to renal and cardiac dysfunction in rats with chronic kidney disease: reduction of PPAR\u03b1","volume":"160","author":"Bian","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0200","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0205","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0210","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124055","article-title":"Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus","volume":"10","author":"Satirapoj","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031974","article-title":"Identification of periostin as a critical marker of progression\/reversal of hypertensive nephropathy","volume":"7","author":"Guerrot","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0225","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1681\/ASN.2007030312","article-title":"Enzyme replacement therapy and Fabry kidney disease: quo vadis?","volume":"18","author":"Warnock","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0230","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0235","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.002_bib0240","doi-asserted-by":"crossref","first-page":"22857","DOI":"10.1002\/jcp.28849","article-title":"Knockdown of periostin attenuates 5\/6 nephrectomy-induced intrarenal renin\u2013angiotensin system activation, fibrosis, and inflammation in rats","volume":"234","author":"Bian","year":"2019","journal-title":"J Cell Physiol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:39:27Z","timestamp":1785253167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2013251423000779"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.05.002","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}